Skip to main content

Table 3 Physical fitness values at baseline (BL) and week-12 (W12)

From: A pilot study of brisk walking in sedentary combination antiretroviral treatment (cART)- treated patients: benefit on soluble and cell inflammatory markers

  All Walk Strength-Walk
BL W12 p BL W12 p BL W12 p
6 min Walking Test
 Distance (m) 642 (605–715) 730 (695–830) <0.0001 620 (590–701) 700 (660–807) <0.0001 684 (634–724) 792 (714–850) <0.0001
 HRmean (bpm) 119 (107–132) 137 (116–152) <0.0001 118 (107–135) 128 (116–154) 0.0003 121 (107–133) 138 (116–153) 0.004
 HRmean (%HRmax) 69 (63–75) 73 (63–75) <0.0001 69 (59–75) 71 (63–83) <0.0001 69 (63–75) 75 (68–79) 0.0005
 Δ[La] (mmol/L) 0.9 (0.2-2.2) 1.9 (0.5-4.1) n.s. 0.8 (0.0-2.3) 1.2 (0.5-2.6) n.s. 1.0 (0.6-2.1) 3.3 (0.7-4.5) n.s.
 Δ RPE 1.0 (0–1) 0.5 (0–2) n.s. 0.5 (0.0-2.0) 0.5 (0.0-0.2) n.s. 1.0 (0.0-1.0) 0.5 (0.2-2.0) n.s.
  1. Values are expressed as median (Q1-Q3). W12 values were compared to BL values by the Wilcoxon matched-pairs signed rank test
  2. HR heart rate, Δ[La ] difference in lactate blood concentration between before and after 6MWT, Δ RPE difference in Rate of Perceived Exertion between before and after 6MWT